Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.

Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing the FDA for removing the GLP-1 medication from its shortage list. The Outsourcing Facilities Association,

Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the company announced Monday.  Patrizia Cavazzoni was formerly director of

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing back an industry veteran to lead its regulatory and drug safety operations.